JAK1 and Alzheimer disease: Abrocitinib, a small-molecule Janus kinase 1 (JAK1) inhibitor, demonstrated superior efficacy in reducing itch and other disease signs of AD than dupilumab in patients with moderate-to-severe AD [4, 5].